Upgrade your membership plan for the full website experience.
View Membership Plans
mike pergine
Contact
Michael C. Pergine
Chief Government Affairs & Policy Officer
Michael is the Chief of Worldwide Government Affairs and Policy for Organon, a US-based multi-national biopharmaceutical company that is the world’s largest MNC focused on improving the health of women. As a founding executive of the multi-billion-dollar Fortune 500 startup, he directs global strategic policy-shaping efforts across the full portfolio of Women’s Health, Biosimilars and Legacy Brands franchises, leads government affairs activities, including US Federal and State actions as well as international efforts, and oversees the strategic alignment of Organon’s comprehensive Environmental Social and Governance (ESG) program with policy-shaping activities, with a focus on Access to Medicine.

Prior to joining Organon, Michael spent twenty-five years at Merck & Co., one of the world’s largest and oldest innovative biopharmaceutical companies, preceded by time as a Senior Performance Improvement Consultant at Ernst & Young, and as a Senior Logistics Analyst at BDM Technologies. While at BDM and E&Y, Michael engaged with eight different companies on three continents, across multiple industry sectors including pharmaceuticals, chemicals, medical devices, consumer goods, telecommunications, electronics, industrial paper and packaging, and transportation.

During his career at Merck, Michael took on twelve different roles across the company. He managed a $1.5 Billion annual P&L, delivered profitable sustained growth and dramatic increases in volume and market share, owned and shaped the global strategy and operations for the GARDASIL franchise (the world’s leading HPV cancer prevention vaccine, available in more than 130 countries and now generating almost $6 Billion annually), engaged in product development activities for multiple assets, managed global supply chains, transformed and led critical functions, negotiated contracts worth more than $200 million annual spend in support of global basic research, designed and implemented innovative business process improvements, led business development and alliance management activities, led 10-year-horizon strategic planning efforts across an integrated R&D, manufacturing & supply and commercial vaccine enterprise, built trusting stakeholder relationships, represented the company to government officials around the world, and built, led and motivated high-performing global teams.

See Full Bio